Pancreatic ductal adenocarcinoma (PDA) is often detected at a late stage, hence the identification of new therapies that have potential to block tumor progression is critical for this lethal disease. N-cadherin upregulation has been observed in many cancers including PDA, however, a causal role for this cell adhesion receptor in disease progression has yet to be defined. The concomitant expression of oncogenic Kras G12D and mutant p53 (Trp53 R172H ) in the murine pancreas results in metastatic PDA that recapitulates the cognate features of human pancreatic cancer providing an excellent animal model to identify genes required for tumor progression. Here we determine the consequences of genetically manipulating N-cadherin expression in a mouse model of PDA. Remarkably, mice with reduced N-cadherin expression (that is, Ncad À/ þ ) survived 25% longer (177 vs 142 days, Po0.05) than animals expressing two wild-type N-cadherin (Cdh2) alleles. The survival benefit is likely due to a cumulative effect of N-cadherin's role in different aspects of tumorigenesis including tumor-cell survival, growth, migration and invasion. Interestingly, reduced hedgehog signaling may contribute to the better prognosis for the Ncad À/ þ mice. Moreover, the matrix metalloproteinase MMP-7, associated with poor prognosis in PDA, was reduced in Ncad À/ þ tumors. Finally, Ncad
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer death with a median survival of o6 months and a dismal 5-year survival rate of o5%. The mortality rate is so high in part because pancreatic cancer usually does not produce symptoms until after it has metastasized, thus rendering the malignancy inoperable. 1 Therefore, treatment strategies that specifically target and prevent metastases have the potential to significantly improve the prognosis of this devastating disease.
Cadherin switching (that is, E-cadherin to N-cadherin) associated with epithelial-mesenchymal transition is implicated in the transition from benign tumors to invasive, malignant cancer and the subsequent metastatic dissemination of tumor cells. 2 Ectopic expression of N-cadherin increases tumor-cell motility, implicating cadherin switching in the regulation of cell behavior. 3, 4 Activating mutations in the human K-ras proto-oncogene are found in over 90% of invasive PDA and are sufficient to initiate the disease in mice. 5 In 450% of PDA cases, missense mutations are found in the p53 tumor-suppressor gene leading to chromosomal instability and malignant progression. 1 Interestingly, oncogenic K-ras is sufficient to upregulate N-cadherin expression in pancreatic ductal cells 6 --8 suggesting that K-ras may have an active role in cadherin switching in pancreatic cancer. In contrast, mutant p53 was shown to decrease N-cadherin expression in the presence of mutant K-ras, 8 suggesting a complex regulation of this cadherin in premalignant versus malignant disease. Importantly, knockdown of N-cadherin in BxPC-3 pancreatic tumor cells led to decreased tumor size and metastases in an orthotopic animal model. 9 Taken together, these studies suggest that interfering with N-cadherin function may prove beneficial in pancreatic cancer.
In this study, we investigated the in vivo role of N-cadherin in the development and progression of PDA. We demonstrate for the first time that interfering with N-cadherin expression is sufficient to prolong survival in a genetically defined murine model of pancreatic cancer. Moreover, these studies indicate that N-cadherin influences various signaling pathways previously shown to be critical for pancreatic cancer.
RESULTS AND DISCUSSION
To determine the consequences of interfering with N-cadherin function in pancreatic cancer, we genetically manipulated Ncadherin expression in a mouse model of PDA. In this model, Pdx1/Cre activates oncogenic K-ras and mutant p53 in the developing pancreas leading to metastatic PDA with a median survival of 5 months. 10 The LSL-K-ras G12D , LSL-Trp53 R172H and Pdx1/Cre (KPC) mice were bred with two independent N-cadherin mutant strains containing either a floxed (Ncad fl ) allele or a germline null (Ncad lacZ ) allele. 11, 12 At the embryonic and adult stage, Pdx1/Cre Ncad fl/fl pancreata appeared normal, indicating that N-cadherin was not required for pancreas development. 13 To confirm N-cadherin was upregulated in murine PDA, we performed immunohistochemistry on KPC Ncad þ / þ tumors.
Heterogeneous N-cadherin expression was observed primarily in less differentiated areas of the tumor, whereas E-cadherin was associated with ductal structures (Figure 1a ). To determine the requirement for N-cadherin in PDA, we examined the survival of the KPC mice with altered N-cadherin gene dosage. Remarkably, KPC Ncad (Figure 1b) . In contrast, there was no significant change in survival between KPC Ncad À/À mice (Ncad fl/fl , n ¼ 14, 140 days; Ncad lacZ/fl , n ¼ 17, 137 days) compared with KPC Ncad þ / þ mice. Hence, the present study will focus on understanding the survival benefit in the KPC Ncad À/ þ mice, and N-cadherin-null tumors will serve as an additional control. To examine N-cadherin expression levels, western analysis was performed on primary tumor-cell lines derived from the KPC mice. As predicted by the genotypes, N-cadherin was reduced in the KPC Ncad À/ þ and absent in the KPC Ncad À/À tumor cells (Figure 1c ). E-cadherin levels were not changed in KPC tumor cells. Moreover, b-catenin and p120-catenin displayed normal expression pattern in KPC tumor cells (Supplementary Figure 1) . Initially, we focused on primary tumors and metastases of terminally ill animals. At the terminal stage, we observed no apparent difference between the tumor pathology of KPC mice regardless of N-cadherin genotype (data not shown). All KPC mice exhibited similar characteristics of end-stage PDA including ascites, regional disease and distant metastasis. The incidence of lymph node, liver and lung metastases was similar between the different N-cadherin genotypes at the terminal stage (Supplementary Table I ). Next, we examined pancreas pathology at an earlier age (Figure 1d ). Tumor development was delayed in the KPC Ncad À/ þ mice compared with KPC Ncad þ / þ and Ncad À/À mice at 3 --4 months of age, consistent with abundant interspersed acini remaining in the KPC N-cad À/ þ pancreas. At this early age, 6 out of 11 KPC Ncad þ / þ animals developed PDA, whereas only 3 out of 10 KPC Ncad À/ þ animals had PDA consistent with a delay in tumor development.
N-cadherin has been implicated in various aspects of tumorigenesis including tumor-cell survival, migration and invasion. 4, 9, 14, 15 To investigate possible explanations for the increased survival of the KPC Ncad À/ þ animals, we first examined tumor-cell survival using the apoptotic marker cleaved caspase-3. Interestingly, large foci of dying cells were observed in the KPC Ncad To investigate the cellular and molecular changes associated with the survival advantage in the KPC Ncad À/ þ animals, tumorcell lines were derived from the KPC mice as previously described. 16 To determine the relative tumorigenicity of the different KPC tumor-cell lines, anchorage-independent cell growth was observed for up to 3 weeks in soft agar. As expected, all the (Figure 2d) . Furthermore, N-cadherin was shown to regulate MMP-9 in breast cancer cells, 3, 15 and it was also decreased in the KPC Ncad À/ þ tumor cells (Figure 2d ). Next we examined the matrix metalloproteinase MMP-7 important for acinar-ductal cell metaplasia and metastasis in animal models, and its expression is associated with poor survival in PDA patients. 21, 22 Importantly, MMP-7 was decreased in the KPC Ncad À/ þ tumors compared with KPC Ncad þ / þ and Ncad 
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À/ þ animals. Moreover, MMP-7 was also decreased in the KPC Ncad À/ þ tumor-cell line (Figure 3b ). N-cadherin has been shown to interact with FGFR, thus facilitating FGF signaling possibly by blocking its ligand-induced internalization, hence increasing FGFR stability on the cell surface.
15 FGFR2 has been implicated in migration and invasion of pancreatic cancer cells, 23 and importantly N-cadherin and FGFR2 co-immunoprecipitate in murine pancreatic tumor cells. 8 Therefore, we examined FGFR2 expression in the KPC tumors. Similar to human PDA, 23 FGFR2 was not only detected at the cell surface but also in the cytoplasm in the KPC tumor cells with no apparent difference in FGFR2 expression between the N-cadherin genotypes (Figure 4a ). FGF10 produced by pancreatic stromal cells stimulates FGFR2 signaling in human pancreatic cancer cells resulting in increased migration and invasion. 23 Importantly, N-cadherin was shown to enhance FGF2/FGFR1 signaling in breast cancer cells leading to sustained activation of the MAPK --ERK pathway. 15 To examine the effect of N-cadherin reduction on FGFR signaling, serum-starved KPC tumor cells were stimulated with FGF10, and MAPK-ERK activation was examined over time (Figure 4b) (Figures 4e and f) , consistent with the idea that these cells are less responsive to FGF stimulation. Moreover, NCAM was increased in the KPC Ncad À/À tumors, suggesting that enhanced NCAM/FGFR signaling may be compensating for loss of N-cadherin.
Perspective
In this study, we demonstrate for the first time that interfering with N-cadherin expression can prolong survival in a spontaneous highly metastatic pancreatic cancer model. 10 To our knowledge, this is the first demonstration of a specific genetic manipulation leading to increased survival in the KPC mouse model. It was reported that pharmacological inhibition of hedgehog signaling plus gemcitabine could extend survival of the KPC animals. 26 Interestingly, it was recently reported that the genetic loss of MMP7 (also decreased in KPC Ncad À/ þ ) was not sufficient to increase survival, although metastasis was decreased in the absence of MMP7. 22 The overall increase in survival of the KPC Ncad À/ þ mice is likely because of N-cadherin's role in multiple pathways critical for tumor progression. We show that altering N-cadherin expression in the context of mutant K-ras and p53 impinges on several key steps of tumor progression including tumor-cell survival, growth, migration and invasion. The decreased response of KPC Ncad À/ þ tumor cells to FGF10 stimulation is consistent with N-cadherin's ability to regulate FGFR signaling in breast cancer cells. 15, 27 Hence, we hypothesize that N-cadherin levels fall below a critical threshold required for effective FGF10/ FGFR2 signaling in KPC Ncad À/ þ tumors. However, it is unlikely that decreased FGF signaling alone is sufficient to prolong survival in the KPC model. Importantly, other molecules known to be involved in PDA were also affected by reduced N-cadherin expression in the KPC model. It is intriguing to speculate that N-cadherin may influence Shh signaling by its ability to bind the cell surface protein Cdo, 28 which can bind directly to Shh. Paradoxically, generating tumors devoid of N-cadherin did not result in a survival advantage, whereas reducing N-cadherin levels prolonged survival of the KPC Ncad À/ þ mice. As the N-cadherin gene is presumably deleted before tumor initiation, the KPC Ncad À/À tumors must rely on an alternative mechanism for the development and progression of PDA. It is remarkable that tumorcell survival, growth, migration and invasion of the Ncad À/À tumor cells were similar to the Ncad þ / þ . We hypothesize that the lack of a survival benefit in the KPC Ncad À/À mice is because of compensation by an alternative cell adhesion receptor. NCAM is a potential candidate, as it interacts with FGFR and it is upregulated in response to loss of E-cadherin 25 similar to N-cadherin. In future studies, it will be interesting to determine the importance of NCAM upregulation in Ncad À/À tumors. The increased survival of the KPC Ncad À/ þ mice is especially exciting, as the N-cadherin antagonist ADH-1 was recently shown to block tumor growth, invasion and metastasis in an orthotopic pancreatic cancer model.
14 ADH-1 is a cyclic pentapeptide that contains the cell adhesion recognition site, His-Ala-Val, which is found in the first extracellular domain of N-cadherin. Furthermore, ADH-1 enhanced the cytotoxic effects of chemotherapy in a melanoma xenograft model resulting in reduced tumor growth. 30 Interestingly, FGFR1 expression decreased in mice treated with the chemotherapeutic agent melphalan plus ADH-1, but not when mice were treated with either compound alone. Of note, ADH-1 recently received orphan drug designation from the Food and Drug Administration for its use in conjunction with melphalan for the treatment of Stage IIB/C, III and IV malignant melanoma. Moreover, monoclonal antibodies against the ectodomain of N-cadherin slowed growth, invasion and metastasis of prostate cancer cells in a xenograft model. 31 Taken together, either interfering with N-cadherin function on the cell surface with an inhibitor or genetically suppressing N-cadherin levels (this study) is sufficient to impede tumor-cell growth, survival, invasion and metastasis, thus supporting N-cadherin as a bona fide therapeutic target for different cancers. In future studies, it will be important to determine whether interfering with N-cadherin function with either ADH-1 or an anti-N-cadherin monoclonal antibody can mimic the N-cadherin haploinsufficiency-survival phenotype in the KPC model.
